ROLE OF OSTEOPROTEGERIN IN THE DEVELOPMENT OF OSTEOPENIC SYNDROME IN CASE OF CHRONIC OBSTRUCTIVE LUNG DISEASE
Abstract
The medical observation of 55 patients aged 44-58 years old suffering from chronic obstructive lung disease has allowed to study the relationship between the levels of osteoprotegerin, markers of bone metabolism, tumour necrosis-a factor in blood serum and bone tissue mineral density. The Dual-energy X-ray absorptiometry was a technique used to measure the bone tissue mineral density. All this allowed diagnosing the osteopenic syndrome in 43 cases and confirming the direct correlation between the content of tumour necrosis-a factor and markers of bone resorption in blood serum, and between the content of osteoprotegerin and bone tissue mineral density.
About the Authors
E. A. Kochetkova
Vladivostok State Medical University
Russian Federation
Russian Federation
K. A. Bourya
Vladivostok State Medical University
Russian Federation
Russian Federation
L. G. Ugay
Vladivostok State Medical University
Russian Federation
Russian Federation
E. A. Kotsyurbiy
Vladivostok State Medical University
Russian Federation
Russian Federation
V. A. Nevzorova
Vladivostok State Medical University
Russian Federation
Russian Federation
P. A. Lukiyanov
Pacific Institute of Bioorganic Chemistry of the FEB RAS
Russian Federation
Russian Federation
S. A. Albavichus
Vladivostok State Medical University
Russian Federation
Russian Federation
References
1. Кочеткова Е.А., Волкова М.В., Гельцер Б.И. Цитокиновый статус у больных хронической обструктивной болезнью легких и его взаимосвязь с функциональным состоянием костной ткани // Тер. архив. 2004. Т. 76, № 3. P. 23-27.
2. Biskobing D.M. COPD and osteoporosis // Chest. 2002. Vol. 121, No. 2. P. 609-620.
3. Bolton C.E., Ionescu A.A., Shiels K.M. et al. Associated loss fat-free mass and bone mineral density in chronic obstructive pulmonary disease // Am. J. Respir. Crit. Care Med. 2004. Vol. 170, No. 12. P. 1286-1293.
4. Dougall W.C., Chaisson M. The RANKL/RANK/OPG triad in cancer-induced bone diseases // Cancer Metastasis Rev. 2006. Vol. 25, No. 4. P. 541-549.
5. Hofbauer L.C., Khosla S., Dunstan C.R. et al. The role of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption // J. Bone Miner. Res. 2000. Vol. 15, No. 1. P. 2-12.
6. Incalzi R.A., Caradonna P., Ranieri P. et al. Correlates of osteoporosis in chronic obstructive pulmonary disease // Respir. Med. 2000. Vol. 94, No. 11. P. 1079-1084.
7. Mezquita-Raya P., Higuera M., Garcia D.F. et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women // Osteoporosis Int. 2005. Vol. 16, No. 11. P. 1368-1374.
8. Monegal A., Navasa M., Peris P. et al. Serum osteoprotegerin and its ligand in cirrhotic patients referred for osteoporotic liver transplantation: relationship with metabolic bone disease // Liver international. 2007. Vol. 27, No. 4. P. 492-497.
9. Pennisi P., Signorelli S.S., Ricobene S. et al. Low bone density and abnormal in patients with atherosclerosis of peripheral vessels // Osteoporosis Int. 2004 Vol. 15, No. 5. P. 389-395.
10. Rogers A., Saleh G., Hannon R.A. et al. Circulating estradiol and osteoprotegerin as determinant of bone turnover and bone density in postmenopausal women // J. Clin. Endocrinol. Metab. 2002. Vol. 87, No. 4. P. 4470-4475.
11. Warren S., Browner W.S., Lui L.Y., Steven R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women // J. Clin. Endocrinol. Metab. 2001. Vol. 86, No. 4. P. 631-637.
Review
For citations:
Kochetkova E.A., Bourya K.A., Ugay L.G., Kotsyurbiy E.A., Nevzorova V.A., Lukiyanov P.A., Albavichus S.A. ROLE OF OSTEOPROTEGERIN IN THE DEVELOPMENT OF OSTEOPENIC SYNDROME IN CASE OF CHRONIC OBSTRUCTIVE LUNG DISEASE. Pacific Medical Journal. 2013;(1):20-22. (In Russ.)
Views:
221
Email this article 